[
    [
        {
            "time": "",
            "original_text": "医药生物行业周报：冠脉支架国采方案落地 头部企业有望相对受益",
            "features": {
                "keywords": [
                    "医药生物",
                    "冠脉支架",
                    "国采方案",
                    "头部企业",
                    "受益"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业周报：冠脉支架国采方案落地 头部企业有望相对受益",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业报告：持续看好流感及肺炎相关疫苗销售 关注医药三季报业绩主线",
            "features": {
                "keywords": [
                    "医药生物",
                    "流感",
                    "肺炎",
                    "疫苗销售",
                    "三季报",
                    "业绩"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业报告：持续看好流感及肺炎相关疫苗销售 关注医药三季报业绩主线",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业跨市场周报：冠脉支架全国集采政策落地 未来或催生两大高耗投资方向",
            "features": {
                "keywords": [
                    "医药生物",
                    "冠脉支架",
                    "全国集采",
                    "政策",
                    "高耗投资"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业跨市场周报：冠脉支架全国集采政策落地 未来或催生两大高耗投资方向",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]